19 research outputs found
ANÁLISE DA EVOLUÇÃO DAS RELAÇÕES DE COAUTORIA NOS PROGRAMAS DE PÓS-GRADUAÇÃO EM COMPUTAÇÃO NO BRASIL
This paper describes the basis for a study of the dynamic relationships of (co- )authorship among full time professors from Brazilian Computer Science graduate programs. 889 researchers were identified, working in 45 graduate programs. A robust entity resolution heuristic was developed, allowing the identification of (co-)authorship relationships among researchers with accuracy above 96%. The social network analysis allowed for the discovery of some interesting phenomena about the dynamics of the Brazilian scientific production, related to the increasing in the production within and among graduate programs.Este trabalho descreve as bases para um estudo da dinâmica de relações de coautoria entre pesquisadores associados aos programas de pós-graduação em Ciência da Computação, avaliados pela CAPES no triênio 2007-2009. Ao todo, foram identificados 889 pesquisadores permanentes nos 45 programas de pós-graduação avaliados. Uma heurística robusta de resolução de entidades foi desenvolvida, possibilitando a identificação das relações de coautoria entre pesquisadores, com uma taxa de acerto superior a 96%. Com base na análise das redes de coautoria foi possível observar fenômenos interessantes da dinâmica da pesquisa brasileira, relacionados especialmente ao aumento da produção conjunta inter e intra programas de pós-graduação
Assessing treatment response to prophylactic lithium use in patients with bipolar disorder
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia A Global Call to Action
Q1Q1Artículo completoE1-E13IMPORTANCE Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated
genetic disorder that leads to premature morbidity and mortality due to atherosclerotic
cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around
the world of every race and ethnicity. The lack of general awareness of FH among the public
and medical community has resulted in only 10% of the FH population being diagnosed and
adequately treated. The World Health Organization recognized FH as a public health priority
in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization
report highlighted 11 recommendations to address FH worldwide, from diagnosis and
treatment to family screening and education. Research since the 1998 report has increased
understanding and awareness of FH, particularly in specialty areas, such as cardiology and
lipidology. However, in the past 20 years, there has been little progress in implementing the
11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire
generation of families with FH.
OBSERVATIONS In 2018, the Familial Hypercholesterolemia Foundation and the World Heart
Federation convened the international FH community to update the 11 recommendations.
Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during
the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as
a platform for the FH community to examine the original recommendations, assess the gaps,
and provide commentary on the revised recommendations. The Global Call to Action on
Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders,
scientific experts, policy makers, and the original authors of the 1998 World Health
Organization report. Attendees from 40 countries brought perspectives on FH from low-,
middle-, and high-income regions. Tables listing country-specific government support for
FH care, existing country-specific and international FH scientific statements and guidelines,
country-specific and international FH registries, and known FH advocacy organizations
around the world were created.
CONCLUSIONS AND RELEVANCE By adopting the 9 updated public policy recommendations
created for this document, covering awareness; advocacy; screening, testing, and diagnosis;
treatment; family-based care; registries; research; and cost and value, individual countries
have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene
associated with FH and, likely, all those with severe hypercholesterolemia as well
Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action
Importance: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. Observations: In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing country-specific and international FH scientific statements and guidelines, country-specific and international FH registries, and known FH advocacy organizations around the world were created. Conclusions and Relevance: By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countries have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene associated with FH and, likely, all those with severe hypercholesterolemia as well
Reducing the clinical and public health Burden of Familial hypercholesterolemia
Importance Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. Observations In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing country-specific and international FH scientific statements and guidelines, country-specific and international FH registries, and known FH advocacy organizations around the world were created. Conclusions and Relevance By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countries have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene associated with FH and, likely, all those with severe hypercholesterolemia as well
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.
Importance: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to 250 people around the world of every race and ethnicity. The lack of general awareness of FH among the public and medical community has resulted in only 10% of the FH population being diagnosed and adequately treated. The World Health Organization recognized FH as a public health priority in 1998 during a consultation meeting in Geneva, Switzerland. The World Health Organization report highlighted 11 recommendations to address FH worldwide, from diagnosis and treatment to family screening and education. Research since the 1998 report has increased understanding and awareness of FH, particularly in specialty areas, such as cardiology and lipidology. However, in the past 20 years, there has been little progress in implementing the 11 recommendations to prevent premature atherosclerotic cardiovascular disease in an entire generation of families with FH. Observations: In 2018, the Familial Hypercholesterolemia Foundation and the World Heart Federation convened the international FH community to update the 11 recommendations. Two meetings were held: one at the 2018 FH Foundation Global Summit and the other during the 2018 World Congress of Cardiology and Cardiovascular Health. Each meeting served as a platform for the FH community to examine the original recommendations, assess the gaps, and provide commentary on the revised recommendations. The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report. Attendees from 40 countries brought perspectives on FH from low-, middle-, and high-income regions. Tables listing country-specific government support for FH care, existing country-specific and international FH scientific statements and guidelines, country-specific and international FH registries, and known FH advocacy organizations around the world were created. Conclusions and Relevance: By adopting the 9 updated public policy recommendations created for this document, covering awareness; advocacy; screening, testing, and diagnosis; treatment; family-based care; registries; research; and cost and value, individual countries have the opportunity to prevent atherosclerotic heart disease in their citizens carrying a gene associated with FH and, likely, all those with severe hypercholesterolemia as well